Cytoparin™ - Cell Therapy/Diabetes Type 1

Patients with severe types of diabetes type 1 have difficulties controlling blood sugar levels, despite modern monitoring equipment and strict insulin regimes.

Islet transplantation is a novel treatment of the disease currently undergoing clinical trials, where isolated islets cells from a donor pancreas are introduced into the patient, to restore glucose level regulation.

Diabetes is a global disease and the WHO projects that “Diabetes will be the 7th leading cause of death in 2030”. Between 1999-2004, 471 patients with type 1 diabetes received islet transplants at 43 institutions worldwide. Registered clinical studies currently include more than 1,000 patients.

During the procedure, allogeneic donor islets are infused into the patient's liver. An adverse immune response and inflammation reaction risks reducing the survival of the infused cell mass by 50-80 %. Due to this destruction of cell mass 2,7 donors is required to successfully treat one patient.

Cytoparin^TM functions as a protective layer shielding islets from the innate immunity response and reduces coagulation and complement activation. By so doing, it has the potential to significantly improve cell mass survival and thus transplant outcome and Corline's goal is a 1-to-1 relationship between donors and patients.

Cytoparin^TM can also be used to protect insulin producing cells in artificial biopancreases - where an artificial organ that regulate insulin is manufactured outside of the body - a growing field within Regenerative Medicine.